1
|
Wang L, Chen S and Xu K: IL-17 expression
is correlated with hepatitis B-related liver diseases and fibrosis.
Int J Mol Med. 27:385–392. 2011.PubMed/NCBI
|
2
|
Liaw YF and Chu CM: Hepatitis B virus
infection. Lancet. 373:582–592. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Cholongitas E, Papatheodoridis GV, Vangeli
M, et al: Systematic review: The model for end-stage liver disease
- should it replace Child-Pugh’s classification for assessing
prognosis in cirrhosis? Aliment Pharmacol Ther. 22:1079–1089.
2005.
|
4
|
Infante-Rivard C, Esnaola S and Villeneuve
JP: Clinical and statistical validity of conventional prognostic
factors in predicting short-term survival among cirrhotics.
Hepatology. 7:660–664. 1987. View Article : Google Scholar : PubMed/NCBI
|
5
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Lok AS and McMahon B: Chronic hepatitis B.
Hepatology. 45:507–539. 2007. View Article : Google Scholar
|
7
|
Iloeje UH, Yang HI, Su J, et al:
Predicting cirrhosis risk based on the level of circulating
hepatitis B viral load. Gastroenterology. 130:678–686. 2006.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Kao JH: Role of viral factors in the
natural course and therapy of chronic hepatitis B. Hepatol Int.
1:415–430. 2007. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhang P, Chen Z, Gong Z, et al: Study on
relationship between Th17 cells, Th17 cytokine and the inflammatory
activity of liver tissue in post hepatitis B cirrhosis. Wei Chang
Bing Xue. 15:456–461. 2010.(In Chinese).
|
10
|
Niedbala W, Wei XQ, Cai B, et al: IL-35 is
a novel cytokine with therapeutic effects against collagen-induced
arthritis through the expansion of regulatory T cells and
suppression of Th17 cells. Eur J Immunol. 37:3021–3029. 2007.
View Article : Google Scholar
|
11
|
Chinese Society of Hepatology, Chinese
Society of Infectious Diseases and Chinese Medical Association.
Viral hepatitis prevention and treatment programs. Zhonghua Gan
Zang Bing Za Zhi. 8:324–329. 2000.(In Chinese).
|
12
|
Chinese Society of Hepatology, Chinese
Society of Infectious Diseases and Chinese Medical Association. The
guideline of prevention and treatment for chronic hepatitis B.
Zhonghua Gan Zang Bing Za Zhi. 13:881–891. 2005.(In Chinese).
|
13
|
Harrington LE, Hatton RD, Mangan PR, et
al: Interleukin 17-producing CD4+ effector T cells develop via a
lineage distinct from the T helper type 1 and 2 lineages. Nat
Immunol. 6:1123–1132. 2005. View
Article : Google Scholar
|
14
|
Infante-Duarte C, Horton HF, Byrne MC and
Kamradt T: Microbial lipopeptides induce the production of IL-17 in
Th cells. J Immunol. 165:6107–6115. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Park H, Li Z, Yang XO, et al: A distinct
lineage of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nat Immunol. 6:1133–1141. 2005. View Article : Google Scholar : PubMed/NCBI
|
16
|
Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS
and Jia JH: Increased Th17 cells contribute to disease progression
in patients with HBV-associated liver cirrhosis. J Viral Hepat.
19:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Ye Y, Xie X, Yu J, et al: Involvement of
Th17 and Th1 effector responses in patients with Hepatitis B. J
Clin Immunol. 30:546–555. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Mangan PR, Harrington LE, O’Quinn DB, et
al: Transforming growth factor-beta induces development of the
T(H)17 lineage. Nature. 441:231–234. 2006. View Article : Google Scholar
|
19
|
Bettelli E, Carrier Y, Gao W, et al:
Reciprocal developmental pathways for the generation of pathogenic
effector TH17 and regulatory T cells. Nature. 441:235–238. 2006.
View Article : Google Scholar
|
20
|
Veldhoen M, Hocking RJ, Atkins CJ,
Locksley RM and Stockinger B: TGFbeta in the context of an
inflammatory cytokine milieu supports de novo differentiation of
IL-17-producing T cells. Immunity. 24:179–189. 2006. View Article : Google Scholar
|
21
|
Olson BM, Sullivan JA and Burlingham WJ:
Interleukin 35: a key mediator of suppression and the propagation
of infectious tolerance. Front Immunol. 4:3152013. View Article : Google Scholar : PubMed/NCBI
|
22
|
Vignali DA and Kuchroo VK: IL-12 family
cytokines: immunological playmakers. Nat Immunol. 13:722–728.
2012.PubMed/NCBI
|
23
|
Collison LW, Chaturvedi V, Henderson AL,
et al: IL-35-mediated induction of a potent regulatory T cell
population. Nat Immunol. 11:1093–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Liu JQ, Liu Z, Zhang X, et al: Increased
Th17 and regulatory T cell responses in EBV-induced gene
3-deficient mice lead to marginally enhanced development of
autoimmune encephalomyelitis. J Immunol. 188:3099–3106. 2012.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Yang J, Yang M, Htut TM, et al:
Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22
and RORgamma t. Eur J Immunol. 38:1204–1214. 2008. View Article : Google Scholar : PubMed/NCBI
|
26
|
Fontenot JD, Gavin MA and Rudensky AY:
Foxp3 programs the development and function of CD4+CD25+ regulatory
T cells. Nat Immunol. 4:330–336. 2003. View
Article : Google Scholar : PubMed/NCBI
|
27
|
Hori S, Nomura T and Sakaguchi S: Control
of regulatory T cell development by the transcription factor Foxp3.
Science. 299:1057–1061. 2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Khattri R, Cox T, Yasayko SA and Ramsdell
F: An essential role for Scurfin in CD4+CD25+T regulatory cells.
Nat Immunol. 4:337–342. 2003. View
Article : Google Scholar : PubMed/NCBI
|
29
|
Zou ZS, Xu DP, Li BS, et al:
Immunologically-competent cells in liver infiltrating lymphocytes
in patients with chronic severe hepatitis B. Zhonghua Yi Xue Za
Zhi. 87:2416–2419. 2007.(In Chinese).
|